Navigation Links
Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%
Date:12/8/2009

ROTTERDAM, The Netherlands, December 8 /PRNewswire/ -- The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported - up to 31%.

Preliminary ERSPC findings* showed that screening reduced prostate cancer deaths by 20%. This latest ERSPC analysis** corrects for non-attendance and contamination to assess the effectiveness of PSA testing in those men actually screened: http://www.erspc.org.com.

From 1992, the ERSPC study randomized 162,000 men, aged 55 to 69, in seven European countries to either a screening arm or a control group. Those screened were given a blood test to detect PSA levels: if it was 3.0ng/ml or more, they were offered a biopsy. Screening took place on average every four years. Mean follow-up was nine years.

In any randomized trial, some in the screening arm do not attend and some in the control group inadvertently receive a PSA test (contamination). Contamination makes it difficult to detect differences. This is believed to be one reason why the Prostate Lung, Colon and Ovarian (PLCO) study failed to detect any significant reduction in mortality.

PSA cut off level of 3ng/ml is safer threshold for reducing biopsies

Using retrospective data from the Dutch arm, the ERSPC has shown that using a screening algorithm - an individual risk assessment - alongside PSA testing can reduce the number of unnecessary biopsies. PSA testing is sensitive but not specific, so elevated levels do not necessarily imply cancer. Approximately 30% of detected cancers are non-aggressive - 'indolent' or slow growing.

Their findings, published in January 2010's European Urology (already online http://www.europeanurology.com/current-issue) suggest that a PSA cut off level of 3ng/ml combined with an individual risk assessment would reduce biopsies by 33%. The majority of cancers potentially missed would be indolent, so there would be no benefit from active treatment. Increasing the PSA cut-off level from 3 to 4 ng/ml may save a similar number of biopsies, but will miss more clinically significant cancers.

*NEJM, March 2009

**European Urology, October 2009

SOURCE European Randomized Study of Screening for Prostate Cancer (ERSPC)


'/>"/>
SOURCE European Randomized Study of Screening for Prostate Cancer (ERSPC)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kline Study: Better Brushing Habits Boost European Oral Care Sales
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. Murad Boosts Skin Immunity With the New Murad(R) Professional Line
4. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
5. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
6. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
7. New Scandinavian collaboration boosts nanotech development
8. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
9. Three Steps to Boost Asymchems Investment in China
10. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
11. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Linda, Ca (PRWEB) , ... February 22, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, is ... will place on February 22 and 23, 2017. This premier, online-only conference focused ...
(Date:2/22/2017)... Dublin - Research ... Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End User, By ... offering. ... Biological Crop Protection Market is forecasted to grow at a CAGR ... biopesticide or biological crop protection market is driven by the surging ...
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon HemopurifierĀ® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennsideā€™s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
Breaking Biology Technology:
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):